Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Invivyd, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
IVVD
Nasdaq
2836
invivyd.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Invivyd, Inc.
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
- Feb 10th, 2025 12:00 pm
Exploring High Growth Tech Stocks in the United States
- Feb 7th, 2025 2:02 pm
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
- Feb 5th, 2025 2:30 pm
Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative
- Feb 4th, 2025 10:30 am
Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025
- Feb 4th, 2025 12:20 am
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
- Feb 3rd, 2025 12:00 pm
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
- Feb 3rd, 2025 11:55 am
We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon
- Jan 30th, 2025 11:16 am
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients
- Jan 27th, 2025 12:01 pm
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
- Jan 10th, 2025 5:12 pm
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
- Jan 10th, 2025 12:01 pm
Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?
- Jan 7th, 2025 2:34 pm
Adagio Medical announces Todd Usen as new CEO and director
- Dec 17th, 2024 11:25 am
Q3 2024 Invivyd Inc Earnings Call
- Nov 15th, 2024 8:17 am
Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
- Nov 15th, 2024 7:11 am
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
- Nov 14th, 2024 1:20 pm
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Nov 14th, 2024 12:05 pm
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
- Nov 14th, 2024 12:01 pm
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
- Nov 12th, 2024 1:30 pm
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
- Nov 6th, 2024 1:01 pm
Scroll